Manufacturers lobby US Congress for assistance to develop orphan products
This article was originally published in Clinica
The US Medical Device Manufacturers Association (MDMA) last week called for legislation to speed up the development of medical devices for diagnosing and treating rare disorders. The concept is similar to the 1983 Orphan Drug Act that has successfully led to advances in pharmaceutical treatments for rare diseases.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.